Article Text

other Versions

PDF
Juvenile idiopathic arthritis: state of the art and future perspectives
  1. Alberto Martini1,
  2. Daniel J Lovell2
  1. 1Dipartimento di Pediatria, Università di Genova, Pediatria II-Reumatologia, IRCCS G Gaslini, Genova, Italy
  2. 2Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
  1. Correspondence to Professor Alberto Martini, Dipartimento di Pediatria, Università di Genova, Pediatria II – Reumatologia, IRCCS G Gaslini, Largo Gaslini 5, 16147 Genova, Italy; albertomartini{at}ospedale-gaslini.ge.it

Abstract

Juvenile idiopathic arthritis (JIA) is not a disease but an exclusion diagnosis that includes all forms of chronic arthritis of unknown origin with onset before 16 years of age. The current classification identifies several different categories. While some of them appear to represent rather homogeneous entities others seem still to include heterogeneous conditions. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of treatments. International research networks of paediatric rheumatology have contributed to fostering the conduct of controlled clinical trials and also the development of validated outcome measures. However, despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.